New drug cocktail shows promise for tough lung cancer
NCT ID NCT03581487
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study tested a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (selumetinib) in 40 people with advanced non-small cell lung cancer that had returned or spread. The goal was to find the safest dose and see if the combo could shrink tumors or slow cancer growth. While not a cure, this approach aims to give patients more control over their disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo shows promise for tough cancers
- New drug combo aims to reboot immune system against lung cancer